New immune cell therapy aims to stop blood cancer relapse after transplant

NCT ID NCT07285668

Recruiting now Disease control Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This early-phase trial tests whether giving patients a special infusion of donor immune cells (with certain T and B cells removed) after a stem cell transplant is safe and can help prevent their blood cancer from coming back. The study enrolls high-risk patients with hard-to-treat leukemias or related cancers. The main goal is to find a safe dose and watch for side effects like graft-versus-host disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Donor immune cells with certain T and B cells removed (TCRαβ+/CD19+ depleted donor lymphocyte infusion)
What this could lead to: If safe and effective, this approach could help prevent blood cancer relapse after a stem cell transplant, improving long-term outcomes for high-risk patients.
What could go wrong: This is a very early, small safety study (Phase I) that is currently suspended. It may not show benefit, and there are risks like graft-versus-host disease or other serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia B-cell chronic lymphocytic leukemia chronic myelogenous leukemia, BCR-ABL1 positive classic Hodgkin lymphoma hematopoietic and lymphoid system neoplasm lymphosarcoma myelodysplastic syndrome primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC MALIGNANCIES

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

UW Carbone Cancer Center
RECRUITING

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.